RBC's James Edwardes Jones Reaffirms Sell Rating on British American Tobacco

RBC's Reaffirmation of Sell Rating

RBC analyst James Edwardes Jones maintained his Sell recommendation on British American Tobacco p.l.c., leaving the target price unchanged at GBX 3,800. The reaffirmation, distributed through the MarketScreener and dpa-AFX Analyser platform, was published on September 11, 2026, and reiterates RBC's prior stance on the stock without introducing a new target or rating change.

Analyst Coverage and Rating Divergence

The RBC Sell stance sits against a mixed analyst backdrop for the stock. On September 10, 2026, Morningstar upgraded British American Tobacco to Buy, according to news headlines tracked on the MarketScreener page, marking a clear divergence from RBC's bearish call. Earlier, on September 2, 2026, UBS issued a Buy rating on British American Tobacco, further underscoring the split in sell-side opinion on the company. Both moves appear as aggregated headline listings rather than full analyst notes within the available source material.

Trading Snapshot and Capital Structure Context

At the time of the RBC note's distribution, British American Tobacco's shares traded around GBX 4,150 on Cboe Europe, up roughly 1.42% intraday, with a year-to-date change near minus 1.85% according to the MarketScreener pricing snapshot. The company has an October 1 ex-dividend date for a 0.6126 GBX distribution noted on the same page. Separately, on September 1, 2026, B.A.T Capital Corporation announced the pricing of a $1.5 billion notes offering, providing recent context on the group's capital-raising activity, though the pricing details are not elaborated in the supplied material.

Operational and Regulatory Backdrop

Headlines listed on the MarketScreener page also reference a September 7 report that a Russian attack damaged a British American Tobacco plant in Ukraine's Chernihiv region, and a separate September 2 notice that the company appointed Dragos Ionut Constantinescu as a director effective September 1, 2026. On the regulatory side, September 2 coverage noted that Altria filed suit against the U.S. FDA over its tobacco product review system, an industry-level development adjacent to British American Tobacco's U.S. operations. These items appear as aggregated headlines and are not the focus of the RBC note itself.

Unresolved Question

The supplied reporting does not detail the specific financial metrics, valuation assumptions, or catalysts cited by James Edwardes Jones in reaffirming the Sell call at GBX 3,800, leaving the underlying rationale for the bearish view unspecified in the available evidence.